Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 27;45(1):32.
doi: 10.1186/s41021-023-00289-y.

Detection of EGFR gene polymorphisms in non-small cell lung cancer Egyptian patients: a case-control study

Affiliations

Detection of EGFR gene polymorphisms in non-small cell lung cancer Egyptian patients: a case-control study

Omali Y El-Khawaga et al. Genes Environ. .

Abstract

Background: Non-Small Cell Lung Cancer displays several genetic mutations including epidermal growth factor receptor. This study's objective was to determine if the EGFR exon19 rs121913438 and exon21 rs121434568 variations play a role in NSCLC susceptibility.

Methods: Case-control research was done at the Mansoura university oncology center including 124 NSCLC patients, and 124 healthy volunteers. blood was used to obtain genomic DNA. ARMS-PCR was used to genotype single-nucleotide polymorphisms.

Results: Molecular study for EGFR exon 19 del. showed NSCLC cases were significantly associated with a higher proportion of heterozygous WD, WD + DD dominant genotypes, and mutant D allele, (p < 0.05 for each), with a risk to develop NSCLC. also, NSCLC cases were significantly associated with a higher proportion of heterozygous TG, TG + GG dominant genotype, G mutant allele, (p < 0.05 for each), with a risk to develop LC (OR > 1 for each). regarding the two EGFR mutations, TTF1 staining was significantly associated with WD + DD genotypes for EGFR exon 19 del But not EGFR exon 21. No substantial differences were found among all studied cases with CK7 or napsin A Tumor cytochemistry.

Conclusions: The WD heterozygous genotype and D allele in exon 19 del. mutation as well as the TG heterozygous and G allele in exon 21 substitution mutation in EGFR gene are strongly associated with the development of advanced-NSCLC in the Egyptians.

Keywords: EGFR gene; Genetic mutation; Lung carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Tetra-ARMS PCR electrophoretic pattern of the EGFR (rs121913438) product, where each lane represents one participant. M stands for DNA marker (100 bp). The internal control is shown by the 444 bp band. Based on the primer, specific 325 bp bands represent the mutant (D) allele, and specific 134 bp bands represent the wild (W) allele. WD heterozygous is represented by lanes 1, 2, 3, and 5. Lane 4 indicates mutant homozygous, where the W allele is absent from the lane and the D allele is present at 325 bp. Lane 6 represents wild-type homozygosity, with the W allele appearing at 134 bp and the D allele absent
Fig. 2
Fig. 2
Individual ARMS PCR electrophoretic pattern of the EGFR gene (rs121434568) product, with each lane representing a different participant. M stands for DNA marker (100 bp). Depending on the primer, specific 199 bp bands represent the T allele, and specific 196 bp bands represent the G allele. The TG heterozygous genotyping is represented by lanes 3, 4, 7, and 8. where lanes 3 and 7 represent the T allele band and lanes 4 and 8 represent the G allele. Lanes 1, 2, 5, and 6 indicate TT homozygosity; whereas the G allele is absent from lanes 2 and 6, the T allele is present on lanes 1 and 5. Lanes 9 and 10 are GG homozygous, with the G allele appearing at 196 bp on lane 10 and the T allele absent from lane 9

Similar articles

References

    1. Ferlay. J, Colombet. M, Soerjomataram. I, Donald M. Parkin, Piñeros. M, Znao. A. Cancer statistics for the year 2020: An overview, Int. J. Cancer 2021, 10.1002/ijc.33588. - PubMed
    1. Cao W, Da Chen HYW, Yu Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Med J. 2021;134(7):783–791. doi: 10.1097/CM9.0000000000001474. - DOI - PMC - PubMed
    1. Ettinger D, Douglas E. NCCN guidelines insights: non-small cell lung cancer, version 1.2020: featured updates to the NCCN guide-lines. J Natl Compr Cancer Netw. 2019;17(12):1464–1472. doi: 10.6004/jnccn.2019.0059. - DOI - PubMed
    1. Tony SM, Yi-Long W, Sumitra T, Chih-Hsin Y, Da-Tong C, Nagahiro S, Patrapim S, Baohui H, Benjamin M, Yukito I, Yutaka N, Yuichiro O. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Eng J Med. 2009;361(10):947–957. doi: 10.1056/NEJMoa0810699. - DOI - PubMed
    1. Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 2017;9(5):1–45. doi: 10.3390/cancers9050052. - DOI - PMC - PubMed